Summit Global Investments Lowers Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Summit Global Investments lessened its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 19,506 shares of the specialty pharmaceutical company’s stock after selling 198 shares during the quarter. Summit Global Investments’ holdings in ANI Pharmaceuticals were worth $1,078,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Thrivent Financial for Lutherans lifted its position in shares of ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after acquiring an additional 299 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after acquiring an additional 310 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after acquiring an additional 412 shares in the last quarter. Natixis Advisors LLC lifted its position in ANI Pharmaceuticals by 2.3% during the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock worth $1,028,000 after buying an additional 417 shares in the last quarter. Finally, US Bancorp DE lifted its position in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 531 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on ANIP shares. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective on the stock. Finally, StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $79.75.

Insider Activity

In related news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,200 shares of company stock valued at $191,776. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ ANIP opened at $64.26 on Friday. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a fifty day simple moving average of $59.39 and a 200-day simple moving average of $58.13. The stock has a market capitalization of $1.40 billion, a PE ratio of -116.84 and a beta of 0.63.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.